|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300073633 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-17 15:45:38 |
|
注册时间: Date of Registration: |
2023-07-17 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
3D打印技术在复杂腹膜后肉瘤的手术指导中的应用:一项回顾性分析 |
|
Public title: |
Application of 3D Printing Technology in Surgical Guidance for Complex Retroperitoneal Sarcoma: A Retrospective Analysis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
3D打印技术在复杂腹膜后肉瘤的手术指导中的应用:一项回顾性分析 |
|
Scientific title: |
Application of 3D Printing Technology in Surgical Guidance for Complex Retroperitoneal Sarcoma: A Retrospective Analysis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林佳鑫 |
研究负责人: |
刁德昌 |
|
Applicant: |
Jiaxin Lin |
Study leader: |
dechang Diao |
|
申请注册联系人电话: Applicant telephone: |
+86 130 6078 3607 |
研究负责人电话: Study leader's telephone: |
+86 134 1611 9782 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13060783607@163.com |
研究负责人电子邮件: Study leader's E-mail: |
diaodechang223@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区大德路111号 |
研究负责人通讯地址: |
广东省广州市越秀区大德路111号 |
|
Applicant address: |
111 Dade Road, Yuexiu District, Guangzhou, Guangdong |
Study leader's address: |
111 Dade Road, Yuexiu District, Guangzhou, Guangdong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州中医药大学 |
||
|
Applicant's institution: |
Guangzhou University of Chinese Medicine |
||
|
研究负责人所在单位: |
广东省中医院 |
||
|
Affiliation of the Leader: |
Guangdong Chinese Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
ZE2023-128-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广东省中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-05-04 00:00:00 |
||
|
伦理委员会联系人: |
李晓彦 |
||
|
Contact Name of the ethic committee: |
Xiaoyan Li |
||
|
伦理委员会联系地址: |
广东省广州市越秀区大德路111号 |
||
|
Contact Address of the ethic committee: |
111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8188 7233 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广东省中医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Guangdong Provincial Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区大德路111号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Retroperitoneal tumor |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究旨在评价基于三维可视化图像的3D打印技术在复杂腹膜后肉瘤手术治疗中的安全性和有效性 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
to evaluate the clinical value of 3D printing technology in guiding the procedure of these tumors. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
接受手术的腹膜后肉瘤患者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Patients undergoing surgery for retroperitoneal sarcoma. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
年龄≤18岁的患者、临床信息缺失的患者、非肉瘤患者、接受多模式治疗的. |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
Patients aged ≤18 years, patients with missing clinical information, non-sarcoma patients, those receiving multimodal treatment |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-08-01 00:00:00至 To 2023-10-05 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-08-01 00:00:00 至 To 2023-08-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
N/A |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |